دورية أكاديمية
Regulation of sialic acid metabolism in cancer.
| العنوان: | Regulation of sialic acid metabolism in cancer. |
|---|---|
| المؤلفون: | Filipsky F; Department of Biomedicine, University Hospital and University of Basel, Switzerland., Läubli H; Department of Biomedicine, University Hospital and University of Basel, Switzerland; Division of Oncology, University Hospital Basel, Switzerland. Electronic address: heinz.laeubli@unibas.ch. |
| المصدر: | Carbohydrate research [Carbohydr Res] 2024 May; Vol. 539, pp. 109123. Date of Electronic Publication: 2024 Apr 22. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0043535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-426X (Electronic) Linking ISSN: 00086215 NLM ISO Abbreviation: Carbohydr Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam : Elsevier Original Publication: Amsterdam. |
| مواضيع طبية MeSH: | Neoplasms*/metabolism , Neoplasms*/pathology , N-Acetylneuraminic Acid*/metabolism , N-Acetylneuraminic Acid*/chemistry, Humans ; Animals |
| مستخلص: | Sialic acid, the terminal structure of cell surface glycans, has essential functions in regulating immune response, cell-to-cell communication, and cell adhesion. More importantly, an increased level of sialic acid, termed hypersialylation, has emerged as a commonly observed phenotype in cancer. Therefore, targeting sialic acid ligands (sialoglycans) and their receptors (Siglecs) may provide a new therapeutic approach for cancer immunotherapy. We highlight the complexity of the sialic acid metabolism and its involvement in malignant transformation within individual cancer subtypes. In this review, we focus on the dysregulation of sialylation, the intricate nature of sialic acid synthesis, and clinical perspective. We aim to provide a brief insight into the mechanism of hypersialylation and how our understanding of these processes can be leveraged for the development of novel therapeutics. Competing Interests: Declaration of competing interest HL received travel grants and consultant fees from Bristol-Myers Squibb (BMS), Alector, InterVenn, GlycoEra, Merck Sharp & Dohme (MSD). HL received research support from BMS, Novartis, GlycoEra and Palleon Pharmaceuticals, and Ono Pharmaceuticals. HL is a cofounder of Glycocalyx Therapeutics AG. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cancer; Hypersialylation; Immunotherapy; Sialic acid; Siglecs |
| المشرفين على المادة: | GZP2782OP0 (N-Acetylneuraminic Acid) |
| تواريخ الأحداث: | Date Created: 20240426 Date Completed: 20240502 Latest Revision: 20240520 |
| رمز التحديث: | 20240520 |
| DOI: | 10.1016/j.carres.2024.109123 |
| PMID: | 38669826 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-426X |
|---|---|
| DOI: | 10.1016/j.carres.2024.109123 |